1. DOP47 Identification and characterization of T-cell receptor sequences associated with Crohn's Disease. (21st January 2022) Authors: Pesesky, M; Carty, C L; Singh, N; Le Bourhis, L; Rosati, E; Bokemeyer, B; Schreiber, S; Görg, S; Gittelman, R M; Dines, J N; Kaplan, I M; Zahid, H J; Baldo, L; Snyder, T M; Robins, H S; Franke, A; Allez, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i096 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP47 Real World Evidence on the effectiveness of ustekinumab in Crohn's Disease: Induction phase results from the prospective, observational RUN-CD Study. (27th May 2021) Authors: Bokemeyer, B; Plachta-Danielzik, S; Di Giuseppe, R; Mohl, W; Teich, N; Hoffstadt, M; Schweitzer, A; von der Ohe, M; Gauss, A; Atreya, R; Krause, T; Blumenstein, I; Höchstödter, J; Hartmann, P; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP77 Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn′s Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study. (21st January 2022) Authors: Di Giuseppe, R; Plachta-Danielzik, S; Bokemeyer, B; Efken, P; Mohl, W; Hoffstadt, M; Krause, T; Schweitzer, A; Schnoy, E; Atreya, R; Teich, N; Trentmann, L; Ehehalt, R; Franzenburg, S; Hartmann, P; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP17 Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study). (21st January 2022) Authors: Plachta-Danielzik, S; di Giuseppe, R; Bokemeyer, B; Efken, P; Mohl, W; Krause, T; Hoffstadt, M; Ehehalt, R; Trentmann, L; Schweitzer, A; Jessen, P; Franzenburg, S; Hartmann, P; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i018 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP36 Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study. (30th January 2023) Authors: Bokemeyer, B; Plachta-Danielzik, S; Deppe, H; Mohl, W; Teich, N; Hoffstadt, M; Schweitzer, A; von der Ohe, M; Gauss, A; Atreya, R; Krause, T; Blumenstein, I; Fajardo Salmon, S; Hartmann, P; Gilman, E; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P091 Switching to TNFi versus non-TNFi biologics in Crohn's Disease patients: Real-world outcomes from a German claims data analysis. (27th May 2021) Authors: Antolin-Fontes, B; Borsi, A; Nissinen, R; Bravatà, I; Barthelmes, J N; Le Bars, M; Lee, J; Maywald, U; Bokemeyer, B; Wilke, T; Ghiani, M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P279 Potential of managed care programmes for patients with inflammatory bowel diseases – results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASEIBD study). (27th May 2021) Authors: Bokemeyer, B; Kaiser, C; Primas, C; Novacek, G; Biedermann, L; Seibold, F; Tappe, U; Bettenworth, D; Graw, J; Hartmann, P; Plachta-Danielzik, S; Schultz, C Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P377 Inadequate response with advanced therapies in real-world patients with Ulcerative Colitis – Results of a German claims database study. (27th May 2021) Authors: Bokemeyer, B; Picker, N; Wilke, T; Rosin, L; Patel, H Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P404 Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany. (27th May 2021) Authors: Picker, N; Bokemeyer, B; Wilke, T; Rosin, L; Patel, H Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P414 Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn′s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study. (30th January 2023) Authors: Bokemeyer, B; Plachta-Danielzik, S; Efken, P; Mohl, W; Hoffstadt, M; Krause, T; Schweitzer, A; Schnoy, E; Atreya, R; Teich, N; Trentmann, L; Ehehalt, R; Franzenburg, S; Hartmann, P; di Giuseppe, R; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i543 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗